文献速递肝病

MELD-GRAIL-Na:肾小球滤过率与肝移植等待名单死亡率

MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List.
PubMed 文献 · Hepatology · 2020-01-29

该研究利用全国数据(n=17,095)开发(2014年)并验证(2015年)了用GRAIL估算的肾小球滤过率(eGFR)替代血清肌酐的MELD-GRAIL-Na模型,以预测肝硬化患者等待名单(WL)死亡率。结果显示MELD-GRAIL-Na是3个月内WL死亡或除名的显著预测因子,在疾病严重程度最高十分位(≥27-40)及女性中预测优于MELD-Na,2015年使用该模型导致16.7%(n=672)的WL患者被重新分类。

要点

  • MELD-GRAIL-Na是3个月内WL死亡或除名的显著预测因子(HR 1.212,95%CI 1.199-1.224)。
  • 在最高疾病严重程度分层(评分≥32)和女性中,MELD-GRAIL-Na预测死亡率更接近观察值。
  • 2015年使用MELD-GRAIL-Na导致16.7%的WL患者被重新分类,可能影响器官分配。

核心结论

  • 纳入eGFR可能比血清肌酐更好地反映真实GFR,尤其在女性中。
  • 采用MELD-GRAIL-Na替代MELD-Na可能影响12%-17%等待移植患者的结局并影响器官分配。

研究设计与样本

  • 研究利用全国数据(n=17,095)开发(2014年)并验证(2015年)预测WL死亡率的模型。
  • GFR通过肝硬化患者中开发的GRAIL方法估算。
  • 采用多变量Cox比例风险模型比较MELD-GRAIL-Na与MELD-Na预测的90天WL死亡率。

主要发现

  • 3个月内,27.8%接受移植,4.3%在WL死亡,4.7%因其他原因除名。
  • GRAIL估算的GFR(HR 0.382,95%CI 0.344-0.424)和MELD-GRAIL-Na(HR 1.212,95%CI 1.199-1.224)是3个月内死亡或除名的显著预测因子。
  • 在疾病严重程度最高十分位(≥27-40),MELD-GRAIL-Na预测观察死亡率更优。
  • 评分≥32时(观察死亡率0.68),预测死亡率MELD-GRAIL-Na为0.67,MELD-Na为0.51。
  • 女性评分≥32时(观察死亡率0.67),预测死亡率MELD-GRAIL-Na为0.69,MELD-Na为0.55。

临床怎么用

  • 在肝硬化等待肝移植患者中,可考虑使用MELD-GRAIL-Na替代MELD-Na以更准确预测WL死亡率,尤其在女性和高疾病严重程度患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Among patients with cirrhosis awaiting liver transplantation, prediction of wait-list (WL) mortality is adjudicated by the Model for End Stage Liver Disease-Sodium (MELD-Na) score. Replacing serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) in the MELD-Na score may improve prediction of WL mortality, especially for women and highest disease severity. APPROACH AND RESULTS: We developed (2014) and validated (2015) a model incorporating eGFR using national data (n = 17,095) to predict WL mortality. Glomerular filtration rate (GFR) was estimated using the GFR assessment in liver disease (GRAIL) developed among patients with cirrhosis. Multivariate Cox proportional hazard analysis models were used to compare the predicted 90-day WL mortality between MELD-GRAIL-Na (re-estimated bilirubin, international normalized ratio [INR], sodium, and GRAIL) versus MELD-Na. Within 3 months, 27.8% were transplanted, 4.3% died on the WL, and 4.7% were delisted for other reasons. GFR as estimated by GRAIL (hazard ratio [HR] 0.382, 95% confidence interval [CI] 0.344-0.424) and the re-estimated model MELD-GRAIL-Na (HR 1.212, 95% CI 1.199-1.224) were significant predictors of mortality or being delisted on the WL within 3 months. MELD-GRAIL-Na was a better predictor of observed mortality at highest deciles of disease severity (≥ 27-40). For a score of 32 or higher (observed mortality 0.68), predicted mortality was 0.67 (MELD-GRAIL-Na) and 0.51 (MELD-Na). For women, a score of 32 or higher (observed mortality 0.67), the predicted mortality was 0.69 (MELD-GRAIL-Na) and 0.55 (MELD-Na). In 2015, use of MELD-GRAIL-Na as compared with MELD-Na resulted in reclassification of 16.7% (n = 672) of patients on the WL. CONCLUSION: Incorporation of eGFR likely captures true GFR better than SCr, especially among women. Incorporation of MELD-GRAIL-Na instead of MELD-Na may affect outcomes for 12%-17% awaiting transplant and affect organ allocation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Asrani SK, Jennings LW, Kim WR, et al. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List. Hepatology. 2020. PMID: 31523825. doi:10.1002/hep.30932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。